scholarly journals An analysis of the ethical frameworks and financial outcomes of corporate social responsibility and business press reporting of US pharmaceutical companies

2021 ◽  
Vol 1 (1) ◽  
pp. 1
Author(s):  
Ivana Zilic ◽  
Helen LaVan ◽  
Lori S. Cook
Keyword(s):  
Corporate Social Responsibility ◽  
Social Responsibility ◽  
Pharmaceutical Companies ◽  
Financial Outcomes ◽  
Business Press ◽  
Ethical Frameworks ◽  
Corporate Social

An exploratory analysis of corporate social responsibility reporting in US pharmaceutical companies

2018 ◽  
Vol 22 (2) ◽  
pp. 197-211 ◽  
Author(s):  
Lori Cook ◽  
Helen LaVan ◽  
Ivana Zilic
Keyword(s):  
Corporate Social Responsibility ◽  
Content Analysis ◽  
Social Responsibility ◽  
Communication Patterns ◽  
Pharmaceutical Companies ◽  
Return On Assets ◽  
Content Type ◽  
Business Press ◽  
Corporate Social Responsibility Reporting ◽  
Corporate Social

Purpose The purpose of this paper is to compare “how we see ourselves” vs “how others see us” when communicating corporate social responsibility (CSR) activities in US pharmaceutical companies. Design/methodology/approach Data were collected as follows: CSR reports from the companies themselves and Business Press reports from the Lexis-Nexis database. NVivo content analysis was used to compare CSR communication by companies and the Business Press. This analysis was comprised of almost 10 million words. Comparisons of Carroll’s framework, including the economic, legal, ethical, and philanthropic categories between CSR reports and the Business Press, were done. Additional analysis was done to discern individual, organizational, and societal patterns of communications. Return on assets was computed for companies that have formal CSR reports and those that do not. Findings The analysis of documents containing almost 10 million words allowed the following conclusions: companies communicate more about their economic and philanthropic activities, and the Business Press communicates more about their legal and ethical activities. The companies and the Business Press communicated similarly about individual CSR. The organization communicated more about organizational topics, and the Business Press communicated less about societal topics. Originality/value This paper makes both substantive and methodological contributions. Its substantive contribution allows an understanding of what pharmaceutical companies need to do to fully communicate their CSR activities. Its methodological contribution is in suggesting that content analysis be used in understanding communication patterns. A levels of analysis approach allowed the discernment of individual-oriented, organizational, and societal-oriented communication patterns.

The Effect of Internal Corporate Social Responsibility on Job Satisfaction: An Empirical Study on Jordanian Pharmaceutical Companies

2020 ◽  
Vol 8 (2) ◽  
pp. 112
Author(s):  
Sura Altheeb ◽  
Kholoud Sudqi Al-Louzi
Keyword(s):  
Job Satisfaction ◽  
Corporate Social Responsibility ◽  
Social Responsibility ◽  
Quantitative Research ◽  
Skills Development ◽  
Future Research ◽  
Pharmaceutical Companies ◽  
Corporate Social ◽  
The Impact ◽  
Positive Results

The current research investigates the impact of internal corporate social responsibility on job satisfaction in Jordanian pharmaceutical companies. Quantitative research design and regression analysis were applied on a total of 302 valid returns that were obtained in a questionnaire based survey from 14 pharmaceutical companies among employees, supervisors and managers. The results showed that internal corporate social responsibility was significantly related to job satisfaction and three of its dimensions, namely working conditions, work life balance and empowerment contributed significantly to job satisfaction, whereas employment stability and skills development had no contribution. This study implies that Jordanian pharmaceutical companies have to try their best to promote and facilitate internal corporate social responsibility among their employees in an effort to improve their job satisfaction, which will eventually yield positive results for the company as a whole. In light of these results, the research presented many recommendations for future research; the most important ones were the application of this study in other sectors, cultures, and countries, and using of multi method for collecting data.

scholarly journals Public health and corporate social responsibility: exploratory study on pharmaceutical companies in an emerging market

2020 ◽  
Vol 16 (1) ◽  
Author(s):  
Tatiana Dănescu ◽  
Maria-Alexandra Popa
Keyword(s):  
Public Health ◽  
Corporate Governance ◽  
Corporate Social Responsibility ◽  
Social Responsibility ◽  
Emerging Economies ◽  
Emerging Market ◽  
Well Being ◽  
Pharmaceutical Companies ◽  
Awareness Campaigns ◽  
Corporate Social

Abstract Background Corporate social responsibility (CSR) is studied from many perspectives and has gained unprecedented importance in recent years, especially in emerging economies. Pharmaceutical companies play a very important role in a population’s well-being and health through the CSR and corporate governance practices that they apply. Methods We used an exploratory approach to measure compliance with the Corporate Governance Code of pharmaceutical companies listed on the Romanian capital market and with practices declared through CSR. Results The results show that pharmaceutical companies are involved in actions that consider the well-being of society by offering financial support and managing various sustainable projects, targeting social and economic issues, leading public health awareness campaigns, and investing in health projects. Conclusion This study highlights the increasingly important role played by corporate governance and corporate social responsibility in pharmaceutical companies in improving public health in countries with emerging economies.

Consistencies and discrepancies in corporate social responsibility reporting in the pharmaceutical industry

2019 ◽  
Vol 10 (2) ◽  
pp. 333-364 ◽  
Author(s):  
Mert Demir ◽  
Maung Min
Keyword(s):  
Corporate Social Responsibility ◽  
Pharmaceutical Industry ◽  
Social Responsibility ◽  
Accurate Information ◽  
Pharmaceutical Companies ◽  
Negative Consequences ◽  
Content Type ◽  
Reporting Practices ◽  
Csr Reporting ◽  
Corporate Social

Purpose This paper aims to examine the consistencies and discrepancies in corporate social responsibility (CSR) reporting by analyzing the CSR reports of pharmaceutical companies. Despite the major role pharmaceutical companies play in the CSR field, our knowledge of the extent to which their disclosures provide comprehensive, material, credible and accurate information on their actual performances is limited because of a lack of sufficient literature on the CSR reporting practices of pharmaceutical companies. Design/methodology/approach The authors present a literature review that serves as the basis to develop the two key research questions: Do pharmaceutical companies publish comprehensive CSR reports? Are company reports that cover more material issues more comprehensive? Using the information on material CSR topics provided by the Sustainability Accounting Standards Board (SASB) and CSR reporting quality scores by the CSR-Sustainability Monitor®, the authors analyzed the CSR reports of the world’s 15 leading pharmaceutical companies. A total of 11 material topics from SASB were mapped onto the corresponding contextual elements in the CSR-Sustainability Monitor. The Monitor evaluates CSR reports published by the world’s largest companies in terms of the degree of transparency and external verification of reporting. Findings The analyses revealed that while the pharmaceutical industry outperforms other industries in terms of the overall comprehensiveness of reporting, certain discrepancies exist among these companies in the content of their disclosures. Specifically, pharmaceutical companies beat the averages on multiple key CSR topics. However, while disclosures on mature areas such as environment and labor relations show some level of standardization, those focusing particularly on sensitive areas such as human rights and supply chain are far from being standardized. The authors also find that CSR reports that do not include all of SASB’s material topics are just as comprehensive as those that do. A detailed analysis of US and non-US companies separately further revealed that this result is valid for both groups of companies. Research limitations/implications Considering the voluntary nature of CSR reporting, pharmaceutical companies still resort to selective disclosure techniques to highlight their achievements in areas where they feel more confident while leaving out others that can have potential negative consequences on the company. These results underscore the evolving nature of CSR reporting in the pharmaceutical industry and call for more attention and further investigation from managers and researchers alike. Originality/value The originality and value of the research show that despite its rapid growth and wide recognition by different segments of society and business as an effective and promising concept, CSR reporting has not yet reached a point where its expected benefits are realized. Focusing on the disclosure side of the story, this paper tries to identify the extent to which the pharmaceutical industry appropriately addresses increasing societal demand for enhanced transparency on its sustainable business policies and practices.

scholarly journals ПОЗИЦІОНУВАННЯ КОРПОРАТИВНОЇ СОЦІАЛЬНОЇ ВІДПОВІДАЛЬНОСТІ ФАРМАЦЕВТИЧНИХ КОМПАНІЙ ЗАСОБАМИ PR

2020 ◽  
pp. 95
Author(s):  
V. Berezenko ◽  
N. Sanakoeva ◽  
T. Ivanets
Keyword(s):  
Corporate Social Responsibility ◽  
Social Responsibility ◽  
International Standards ◽  
Necessary Condition ◽  
Corporate Ethics ◽  
Pharmaceutical Companies ◽  
Main Task ◽  
Main Emphasis ◽  
Business Entities ◽  
Corporate Social

<div><p><em>The main emphasis is paid to the study of business social responsibility to the society. In particular, the experience of corporate social responsibility of business in the field of pharmacy on the basis of the activities of the companies «Pharmak», «Darnitsa» and «Bayer» is analyzed.</em></p></div><p><em>The essential features of the concept of «social responsibility of business» are investigated and the necessity of implementation of social responsibility in the system of strategic management of pharmaceutical companies as a necessary condition for ensuring their competitiveness is grounded. Importance of the initial formation of a correct and effective strategy for positioning of pharmaceutical companies social responsibility along with tracing its relevance, maintaining the attractiveness of the position for target consumers were accentuated.</em></p><p><em>In a scientific research it was revealed that according to European practice corporate social responsibility extends to seven areas: respect for the human rights; compliance with legal requirements; business and corporate ethics; protection of the environment; cooperation with stakeholders: employees, consumers, shareholders, the community, business entities; observance of international standards of behavior; transparency and accountability.</em></p><p><em>The study found that a basic level of a social responsibility is a necessary component of the activities of economic entities that implement this policy. Struggle for personal reputational capital is the main task of increasing the volume of goodwill for any pharmaceutical company. Pharmaceutical companies are trying to show humanization of their business, their social responsibility to society and involve all PR tools.</em></p><p><strong><em>Key words:</em></strong><em> positioning, corporate social responsibility of business, meansof PR, reputation capital.</em></p>

scholarly journals Employee Satisfaction, Corporate Social Responsibility and Financial Performance

2021 ◽  
Vol 13 (18) ◽  
pp. 9996
Author(s):  
Chu-Hsuan Chang ◽  
Hsiou-Wei Lin ◽  
Wen-Hsien Tsai ◽  
Wei-Liang Wang ◽  
Cheng-Tsu Huang
Keyword(s):  
Corporate Social Responsibility ◽  
Social Responsibility ◽  
Financial Performance ◽  
Employee Turnover ◽  
Direct Benefit ◽  
Financial Outcomes ◽  
Corporate Social ◽  
Original Equipment Manufacturers ◽  
The Relationship

This study explores the extent to which employee turnover, a proxy variable to employee loyalty, helps mediate the relationship between Taiwanese firms’ corporate social responsibility (CSR) performance and financial outcome. The results show that a firm’s CSR performance is negatively correlated with employee turnover and turnover variability, and moreover, employee turnover is negatively correlated with a firm’s financial performance. The result is especially noteworthy for studies regarding Taiwanese companies since quite a few of them are original equipment manufacturers (hereafter also referred to as OEMs), of intermediate goods. For the sample firms, although the contribution of social responsibility appears to have insignificantly direct benefit on financial performance, we document that the extent to which CSR conducts influence on long-term financial outcomes may be moderated and mediated by employee enthusiasm.

scholarly journals Pharmaceutical Industry’s Engagement in the Global Equitable Distribution of COVID-19 Vaccines: Corporate Social Responsibility of EUL Vaccine Developers

Vaccines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1183
Author(s):  
Meekang Sung ◽  
Yangmu Huang ◽  
Yuqi Duan ◽  
Fangjing Liu ◽  
Yinzi Jin ◽  
...  
Keyword(s):  
Corporate Social Responsibility ◽  
Social Responsibility ◽  
Vaccine Delivery ◽  
Pharmaceutical Companies ◽  
Social Responsibilities ◽  
Intellectual Property Management ◽  
The Status ◽  
Corporate Social ◽  
Vaccine Distribution ◽  
Lower Income Countries

(1) Objectives: Inequality in the global distribution of COVID-19 vaccines has brought about great challenges in terms of resolving the pandemic. Although vaccine manufacturers are undoubtedly some of the most influential players, studies on their role in global vaccine distribution have been scarce. This study examined whether the pharmaceutical industry is acting according to the principles of corporate social responsibility (CSR) during the pandemic. (2) Methods: Three categories were used to analyze the CSR of vaccine developers. The first was research and development: effectiveness, funding, and profits were measured. The second was transparency and accountability: the transparency of clinical trials and vaccine contracts was analyzed. The final was vaccine delivery: the status of the provision of vaccines to COVAX and lower-income countries, intellectual property management, manufacturing agreements, and equitable pricing were measured. (3) Results: Vaccine developers have acquired large profits. The vaccine delivery category faces the most challenges. Participation of pharmaceutical companies through COVAX was significantly low, and most vaccine supply agreements were secretive, bilateral deals. It was not clear if companies were maintaining equitable pricing. The evaluation indicated that the companies’ CSR practices have differed during the pandemic. (4) Conclusions: Our study contributes to the methodology of assessing the CSR of vaccine developers. This would help understand the current COVID-19 vaccine distribution inequality and propose that pharmaceutical companies re-examine their roles and social responsibilities.

Sign in / Sign up

Export Citation Format

Share Document